Table 1.
Patient characteristics.
| Infliximab (n = 16) | VGIH (n = 15) | |
|---|---|---|
| Sex (males), n (%) | 10 (62.5) | 11 (73.3) |
| Median age at enrollment, years (range) | 2.5 (1–6) | 3.0 (1–4) |
| 1 to <2, n (%) | 2 (12.5) | 2 (13.3) |
| 2 to <10, n (%) | 14 (87.5) | 13 (86.7) |
| Median height, cm (IQR) | 94.0 (86.5–102.5) | 92.0 (89.0–96.0) |
| Median weight, kg (IQR) | 13.75 (11.50–16.95) | 13.20 (12.00–14.30) |
| Presence of complications, n (%) | 7 (43.8) | 6 (40.0) |
| Median duration of KD before starting treatment, days (IQR) | 7.0 (6.0–7.0) | 7.0 (6.0–7.0) |
| Major symptoms of KD, n (%) | ||
| Fever for ≥5 days | 16 (100.0) | 15 (100.0) |
| Bilateral bulbar conjunctival congestion | 15 (93.8) | 15 (100.0) |
| Lip/oral cavity changes | 16 (100.0) | 15 (100.0) |
| Polymorphous rash | 16 (100.0) | 15 (100.0) |
| Distal extremity changes | 16 (100.0) | 15 (100.0) |
| Non-suppurative cervical lymphadenopathy | 15 (93.8) | 15 (100.0) |
| Median body temperature at enrollment, °C (IQR) | 38.80 (38.40–39.75) | 38.60 (37.70–39.50) |
| Median body temperature on day 0, °C (IQR) | 39.40 (38.00–40.15) | 38.80 (38.50–39.90) |
| Concomitant acetylsalicylic acid, n (%) | 15 (93.8) | 15 (100.0) |
| Concomitant systemic corticosteroids, n (%) | 0 | 0 |
| Treatment after withdrawal from the trial, n (%) | (n = 5) | (n = 9) |
| Immunoglobulins | 3 (60.0) | 3 (33.3) |
| Systemic corticosteroids | 1 (20.0) | 0 |
| Cyclosporine | 1 (20.0) | 1 (11.1) |
| Acetylsalicylic acid | 1 (20.0) | 0 |
| Infliximab (Remicade®) | 0 | 5 (55.6). |
| Plasmapheresis | 2 (40.0) | 3 (33.3) |
KD, Kawasaki disease; IQR, interquartile range; VGIH, polyethylene glycol-treated human immunoglobulin.